4D Pharma PLC (LON:DDDD) will present data today outlining how its microbiome-based cancer treatment might activate the body’s response to the disease.
The company’s lead oncology candidate is MRx0518, a strain of live bacteria extracted from human faecal samples that in pre-clinical models has shown it can stimulate the immune system.
Duncan Peyton, chief executive, will highlight aspects of the mode of action of MRx0518 at the Microbiome R&D and Business Collaboration Forum in Rotterdam.
Specific component
4D has identified a specific component of the bacteria, flaA, that plays a key role in the activity of MRx0518 and the body's response to cancer.
Peyton said: "This is a key step in the development of a true microbiome-derived pharmaceutical product for the treatment of cancer.
"Understanding the mode of action of MRx0518, through the identification of a specific gene product and its interaction with a high profile human oncology target, gives greater insight into its potential applications and benefits to cancer patients.”
Plans are at an advanced stage to open clinical studies for MRx0518 in the UK and the US in the near future.
